FOSUN

TOWARDS A BRIGHTER LIFE

Twitter

Facebook

Linkedin

YouTube

WeChat

Weibo

Douyin(Tik Tok)

HONG KONG, CHINA
Address : Room 808, Icbc Tower, 3 Garden Road, Central
Tel : + 852 2509 3228
Fax : + 852 2509 9028

SHANGHAI, CHINA
Address : Building S1, Bund Finance Center, No. 600, Zhongshan East 2nd Road, Huangpu District
Tel : + 86 21 2315 6666
Fax : + 86 21 6130 3288
Postcode : 200010

BEIJING, CHINA
Address : Fosun International Center, No. 237,
Chaoyang North Road, Chaoyang District, Beijing
Tel : + 86 10 59152299

NEW YORK, USA
Address : 28 Liberty Street, 44th Floor, New York, NY 10005, USA
Tel : +1 646 553 5892

PARIS, FRANCE
Address : 15/17 Rue Scribe - 75009 Paris
Tel : 00 33 (0) 1 46461199

LONDON, UK
Address : Units 18 & 19, Part First Floor, The Royal Exchange, London EC3 3LN
Email : londonoffice@fosun.com

LISBON, PORTUGAL
Address : Largo Do Chiado 8, 1249-125 Lisbon, Portugal
Tel : + 351 213 401 500



FOSUN 复星

Rooted in China, Creating a Global Happiness Ecosystem
Fulfilling the Needs of One Billion Families Worldwide in Health, Happiness and Wealth

FOSUN (May 2023)

CONTENTS

02 About Fosun

10 Business Overview

22 Fosun's Strategy

36 Our Pursuit

Unless otherwise specified, all figures in this brochure are as of 31 December 2022

FOSUN, TOWARDS A BRIGHTER LIFE

MISSION


Creating happier lives
for families worldwide

VISION

Rooted in China, Fosun is committed to creating
a global happiness ecosystem fulfilling the needs of
one billion families in Health, Happiness, and Wealth

VALUE

Self-improvement, Teamwork, Performance,
and Contribution to Society



A GLOBAL INNOVATION-DRIVEN CONSUMER GROUP

ABOUT FOSUN

Fosun was founded in 1992. Our mission is to provide high-quality products and services for families around the world in Health, Happiness, Wealth, and Intelligent Manufacturing segments

Total Revenue
10-year Compound Growth 13%
175.39 billion

Total Assets
823.1 billion

Number of Employees
108,000

Forbes Global Ranking 2022
NO. 589

ESG Rating
AA MSCI A HSI

Global Operations
35+ Countries and regions with revenue exceeding RMB100 million

R&D Investment
10.4 billion

1,771 Patents for inventions

10+ Global technology innovation centers

Number of C-end Customers
464 million
Cumulative operable members[1]

* Currency in RMB and data as of 31 December 2022 unless otherwise specified
[1] Operable members: Customers who have agreed to official member terms and conditions of the brand, have granted private personal information, including phone numbers, and are identifiable, reachable and traceable, are defined as registered members (i.e. operable members). From 2022 onwards, this statistic includes consumers in the Fosun Health ecosystem



ROOTED IN CHINA, DEVELOPING GLOBALLY

Over the past 30 years, Fosun has implemented the twin-driver strategy of “Profound Industry Operations + Industrial Investment" to strengthen its foothold in various industries. Through continuous innovation, Fosun has achieved rapid development by capitalizing on the opportunities and momentum of China and the world's economic development



1992
Fosun was founded with a capital of RMB 38,000

1994
Fosun Pharma
Forte

1998
Fosun Pharma was listed on China's A-share market

2002
Yuyuan Inc.

2003
Nanjing Iron & Steel
Sinopharm Group

2007
Hainan Mining
Fosun International(00656.HK) was listed on HKEX

2010
Club Med
Henlius

2011
BFC

2012
Pramerica Fosun Life Insurance
Peak Reinsurance
Starcastle Senior Living

2013
Atlantis Sanya
Foshan Fosun Chancheng Hospital
Sisram Med

2014
Fidelidade
Luz Saúde
Roc Oil

2015
Privatization of Club Med
Thomas Cook
Silver Cross

2016
Gland Pharma
HAL
Wolverhampton Wanderers
Babytree
AHAVA

2017
Fosun United Health Insurance
Dongjia APP

2018
LANVIN
Wolford
Lovelink (formerly known as Baihe Jiayuan)
Songhelou
Fosun Tourism Group was listed on HKEX

2019
FFT
Shanghai Henlius was listed on HKEX

2020
DJULA
WEI
Shede Spirits

2021
Sergio Rossi
Bankhaus Lampe
Wansheng

2022
Lanvin Group was listed on NYSE
Yelanggujiu

LEADERSHIP



Guo Guangchang

Executive Director
Chairman of the Company

Aged 55, is an Executive Director and Chairman of the Company and the founder of the Group. As at the end of the Reporting Period, he has also been a director of both Fosun Holdings and Fosun International Holdings (the direct and indirect controlling shareholders of the Company, respectively), honorary chairman of The Zhejiang Chamber of Commerce, Shanghai, etc.. Mr. Guo was honored, among others, the "China Democratic League Anti-COVID-19 Outstanding Individual" , the "Anti-epidemic Action Award" at the "2020 Ram Charan Management Practice Awards" hosted by Harvard Business Review (Chinese version), the "Outstanding Businessman of Listed Company Award" at the "Top 100 Hong Kong Listed Company" Award, co-organized by Tencent News and Finet Group Limited, and "Lifetime Achievement Award" at the 16th CNBC Asia Business Leaders Award Ceremony etc.. Mr. Guo received a bachelor's degree in philosophy in 1989 and a master's degree in business administration in 1999, both from Fudan University.



Wang Qunbin

Executive Director
Co-Chairman of the Company

Aged 53, is an Executive Director and Co-Chairman of the Company, and the founder of the Group. Mr. Wang was a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE) and Sinopharm (listed on the Hong Kong Stock Exchange). Mr. Wang was awarded "Asia Pacific Outstanding Entrepreneur Awards" by Enterprise Asia and "Best Asian Corporate Director" at the Asian Excellence Recognition Awards by Corporate Governance Asia , etc., and was named one of "China's 50 Top-performing Corporate Leaders" by Harvard Business Review. Mr. Wang received a bachelor's degree in genetic engineering from Fudan University in 1991.



Chen Qiyu

Executive Director
Co-CEO of the Company

Aged 50, is an Executive Director and Co-CEO of the Company. Mr. Chen joined the Group in 1994 and as at the end of the Reporting Period, he has also been a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE) and Shanghai Henlius (listed on the Hong Kong Stock Exchange), a non-executive director and vice chairman of Sinopharm (listed on the Hong Kong Stock Exchange), a director of Gland Pharma (listed on the BSE Limited and National Stock Exchange of India Limited) and various companies within the Group. Mr. Chen was a director of Dian Diagnostics Group Co., Ltd. (listed on the Growth Enterprise Market Board of the Shenzhen Stock Exchange) and Sanyuan Foods (listed on the SSE), a non-executive director of BabyTree (listed on the Hong Kong Stock Exchange) and a co-chairman of New Frontier Health Corporation (delisted from the NYSE in January 2022). As at the end of the Reporting Period, Mr. Chen has been the chairman of China Medical Pharmaceutical Material Association, a vice chairman of China Pharmaceutical Innovation and Research Development Association, the honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association, a member of the 14th Shanghai Standing Committee of the Chinese People's Political Consultative Conference etc.. Mr. Chen was awarded "Asia's Best CEO" by Corporate Governance Asia , etc.. Mr. Chen received a bachelor's degree in genetics from Fudan University in 1993 and an EMBA degree from China Europe International Business School in 2005.



Xu Xiaoliang

Executive Director
Co-CEO of the Company

Aged 49, is an Executive Director and Co-CEO of the Company. Mr. Xu joined the Group in 1998, and as at the end of the Reporting Period, he has also been a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE), an executive director and chairman of FTG (listed on the Hong Kong Stock Exchange), a director of Yuyuan (listed on the SSE), Shanghai Foyo Culture & Entertainment Co., Ltd. (delisted from the NEEQ in April 2021) and various companies within the Group. Mr. Xu was a non independent director of Hainan Mining (listed on the SSE), a non-executive director and vice chairman of Zhaojin Mining Industry Co., Ltd. (listed on the Hong Kong Stock Exchange), and a director of Shanghai Resource Property Consulting Co., Ltd. (delisted from the NEEQ in December 2020). As at the end of the Reporting Period, Mr. Xu has been a deputy to the 15th Shanghai Municipal People's Congress and the chairman of Shanghai International Fashion Federation. Mr. Xu was awarded "Asia's Best CEO" by Corporate Governance Asia , the "Shanghai 4 May Youth Medal" and "Shanghai Top Ten Youth Business People" etc.. Mr. Xu received a master's degree in business administration from the East China Normal University in 2002 and received an EMBA degree from Fudan University in 2019.



Gong Ping

Executive Director
Executive President and CFO of the Company

Aged 47, is an Executive Director, Executive President and CFO of the Company. Mr. Gong joined the Group in 2011 and as at the end of the Reporting Period, he has also been a director of Yuyuan (listed on the SSE) and various companies within the Group. He used to serve as a senior assistant to president of the Group, the general manager of Corporate Development Department and the CEO of Fosun Hive. He was the chairman of PAREF (listed on the Euronext Paris), a non-executive director of Shanghai Zendai Property Limited (listed on the Hong Kong Stock Exchange) and Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE), and a director of Shanghai Bailian Group Co., Ltd. (listed on the SSE) and Resource Property (delisted from the NEEQ in December 2020). Prior to joining the Group, Mr. Gong worked at Pudong branch and the headquarters of Bank of Shanghai as well as the PRC headquarters of Standard Chartered Bank. Mr. Gong also served as a global strategist at the headquarters of Samsung Group in Korea, carrying out special assignments across various sectors including financial services, technology and real estate worldwide. As at the end of the Reporting Period, Mr. Gong has been a council member of Shanghai Association for Youth Entrepreneurship and Employment. Mr. Gong graduated from Fudan University in 1998 with a bachelor's degree in international finance, and then obtained his master's degree in finance from Fudan University in 2005. Mr. Gong also received his master's degree in business administration from International Institute for Management Development (IMD) in Lausanne, Switzerland in 2008.



Huang Zhen

Executive Director
Executive President of the Company

Aged 51, is an Executive Director and Executive President of the Company. Mr. Huang joined the Group in 2017 and as at the end of the Reporting Period, he has also been the chairman of Yuyuan (listed on the SSE), the director of Shede Spirits (listed on the SSE), Resource Property (delisted from NEEQ in December 2020), Shanghai Bailian (listed on the SSE), Sanyuan Foods (listed on the SSE), FTG (listed on the Hong Kong Stock Exchange) and various companies within the Group. Mr. Huang was a non-executive director of Zhaojin Mining (listed on the Hong Kong Stock Exchange). Before joining the Group, Mr. Huang was the deputy general manager of Shanghai Jahwa United Co., Ltd., and the general manager of Shanghai Herborist Cosmetics Co., Ltd., etc.. As at the end of the Reporting Period, Mr. Huang has been a member of the 14th Shanghai Standing Committee of the Chinese People's Political Consultative Conference, a member of the 3rd Shanghai Huangpu District Standing Committee of the Chinese People's Political Consultative Conference, the chairman of Shanghai Huangpu District Federation of Industry and Commerce, the president of Shanghai Huangpu District Chamber of Commerce, the vice chairman of China Gold Association and Gems & Jewelry Trade Association of China, etc.. Mr. Huang was awarded "Top Ten Economic Figures in China's Circulation Industry" and "National Outstanding Commercial Entrepreneur" , etc.. Mr. Huang received a bachelor's degree in economics from Shanghai University of Finance and Economics in 1994 and an MBA degree from Webster University (USA) in 1998.




Pan Donghui

Executive Director
Executive President and CHO of the Company

Aged 53, is an Executive Director, Executive President and chief human resources officer (CHO) of the Company. Mr. Pan joined the Group in 1994 and as at the end of the Reporting Period, he has also been a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE) and FTG (listed on the Hong Kong Stock Exchange) and a director of Shanghai Foyo Culture & Entertainment Co., Ltd. (delisted from NEEQ in April 2021). Mr. Pan also served as a director of Shanghai Ganglian E-Commerce Holdings Co., Ltd. (listed on the Shenzhen Stock Exchange). Mr. Pan obtained a bachelor's degree in engineering from Shanghai Jiaotong University in China in 1991, and a master's degree in business administration from the University of Southern California in the United States in 2009.

GLOBAL BUSINESS FOOTPRINTS

- HEALTH
- HAPPINESS
- WEALTH
- INTELLIGENT MANUFACTURING



U.K.
- Wolverhampton Wanderers
- Resolution Property
- Silver Cross

FRANCE
- Club Med
- LANVIN
- TRIDEM
- PAREF
- DJULA
- St Hubert

AUSTRIA
- Wolford

GERMANY
- HAL
- FFT
- NAGA
- Koller
- Tom Tailor

U.S.
- 28 Liberty
- Fourtrees
- Everest
- St. John
- WEI

CHINA
- Fosun Pharma
- Fosun Kite
- Henlius
- Sinopharm
- Fosun Aitrox
- Fosun Health
- Foshan Fosun Chancheng Hospital
- Yuyuan Inc.
- Yuyuan Tourist Mart
- Laomiao
- Shede Spirits
- Fosun Watch Group
- Tong Han Chun Tang
- Fosun Tourism Group
- Atlantis Sanya
- Lanvin Group
- Pramerica Fosun Life Insurance
- Peak Reinsurance
- Fosun Capital
- Fosun RZ Capital
- Fosun Wealth
- Fosun International Center
- BFC
- Nanjing Iron & Steel
- Hainan Mining
- Easun Techonology
- JEVE
- Fusionride

PORTUGAL
- Fidelidade
- BCP
- Luz Saúde
- Fosun Hive Iberia

JAPAN
- IDERA
- Tomamu
- The Court
- MIRAI

SINGAPORE
- Fosun Hive Capital Management

PERU
- La Positiva

INDIA
- Gland Pharma
- Delhivery

ITALY
- The Medelan
- Sergio Rossi
- Caruso

BRAZIL
- Rio Bravo
- Guide

ISRAEL
- Sisram Med
- AHAVA

AUSTRALIA
- Roc Oil

FOSUN FAMILY HOUSEHOLD CONSUMPTION ECOSYSTEM

As a global innovation-driven consumer group, Fosun is dedicated to developing a global FC2M ecosystem focusing on health, happiness and wealth. The “F” in FC2M stands for both “Family” and “Fosun”; C2M stands for Client to Maker



BUSINESS OVERVIEW

FOSUN FAMILY HOUSEHOLD CONSUMPTION ECOSYSTEM

HEALTH

FOSUN PHARMA 复星医药
Henlius
FOSUNKite 复星凯特生物
FOSUN IDGENVAX 复星安特金
GLAND
FOSUN HEALTH 复星健康
佛山复星禅诚医院 Foshan Fosun Chancheng Hospital
FOSUN MEDTECH 复星医疗器械
sisram medical
博毅雅
FOSUN DIAGNOSTICS 复星诊断
复星杏脉 FOSUN AITROX
复星星堡 FOSUN STARCASTLE
宝宝树 babytree

HAPPINESS

豫园股份 YUYUAN Inc.
FOSUN Holiday 复星旅文
LANVIN GROUP 复朗集团
Club Med 地中海俱乐部
ATLANTIS SANYA 三亚·亚特兰蒂斯
复游会 For you Club
LANVIN PARIS
sergio rossi
ST. JOHN
Wolford
CARUSO
老庙
亞一 让爱相随
DJULA PARIS
AHAVA
豫园商城 YUYUAN GARDEN MALLS
童涵春堂 TONG HAN 1783 CHUN TANG
松鹤楼 Song helou
南翔 NANXIANG STEAMED BUN RESTAURANT
SEA-GULL 海鸥
SHANGHAI since 1955
舍得酒业 SHEDE SPIRITS
夜郎古酒
Wolverhampton Wanderers FC
Lovelink
薄荷健康
St Hubert 圣悠活
Silver Cross

WEALTH

FIDELIDADE SEGUROS DESDE 1808
La Positiva Seguros
HAUCK AUFHÄUSER LAMPE
Millennium bcp
PeakRe
NAGA
Guide
FOSUN CAPITAL 复星创富
复星锐正 FOSUN RZ CAPITAL
FOSUN WEALTH 复星财富
IDÉRA CAPITAL MANAGEMENT
28 LIBERTY
BFC THE BUND FINANCE CENTER 外滩金融中心

INTELLIGENT MANUFACTURING

NISCO
海南矿业 HAINAN MINING
JEVE 捷威动力
翌耀科技 EASUN TECHNOLOGY
复睿智行 FUSIONRIDE
万盛股份 WANSHENG

HEALTH

Transform the industry with technology to create healthier lives
Fosun adopts a global R&D + diversified innovation model (investment, incubation, BD, etc.) to create high-value innovative products in the fields of pharmaceutical, devices, and diagnosis

PHARMACEUTICALS

Fosun Pharma continues to increase investment in innovation and R&D to promote innovative transformation, and focuses on the three major business divisions of innovative medicines business, established medicines manufacturing and supply business and vaccines business

FOSUN PHARMA 复星医药 | FOSUNKite 复星凯特生物 | Henlius | FOSUN ADGENVAX 复星安特金 | GLAND

MEDICAL DEVICES & DIAGNOSTICS

The medical devices & diagnostics segment has initially formed three business divisions focusing on medical cosmetology, health, and professional medical care

FOSUN MEDTECH 复星医疗器械 | sisram medical | 博毅雅 | INTUITIVE FOSUN 直观复星 | CHINDEX

Medical Diagnostics: Integrate innovative diagnostic technologies to protect health for all

FOSUN DIAGNOSTICS 复星诊断



Comprehensively promoted the operation integration of the diagnostic sector and established six major R&D & production bases. The business mainly includes immunodiagnosis, biochemical diagnosis, microbial diagnosis, molecular diagnosis, and Point-Of-Care Testing (POCT)



In June 2022, the F-C800p fully automated biochemical analyzer was approved for registration. After being connected with F-i3000, Fosun Diagnostics' FCi biochemical and immunological pipeline was formed to fully meet the testing needs of clinical departments

HEALTHCARE SERVICES

Accelerate online and offline integration and service network construction, and build a one-stop active health management model (FHMO) that integrates medicine and healthcare throughout the treatment course

FOSUN HEALTH 复星健康 | 佛山复星禅诚医院 Foshan Fosun Chancheng Hospital | JOYFUL WAY 卓尔荟 | 国药集团 SINOPHARM | 国药控股 SINOPHARM GROUP | 复星杏脉 FOSUN AITROX | LUZ SAÚDE

Over 30%

Revenue contribution of new and sub-new products

Over 260

Pipeline projects on innovation drugs, biosimilars, generic drugs, and consistency evaluation items

The world's first PD-1 inhibitor approved for the first-line treatment of small cell lung cancer (SCLC)

Han Si Zhuang 汉斯状®
Approved for three indications in China: MSI-H, sqNSCLC and ES-SCLC; SCLC indication was granted Orphan Drug Designation by the U.S. FDA and the European Commission (EC), the marketing authorization application (MAA) for the treatment of ES-SCLC in Europe was accepted by the European Medicines Agency (EMA)

More than 31 million doses of Comirnaty (mRNA COVID-19 vaccine)

Had been administered in Hong Kong SAR, Macau SAR and Taiwan region since its launch to end of February 2023

More than 300

da Vinci Surgical Systems installed in Chinese mainland, Hong Kong SAR and Macau SAR as of 31 December 2022

Over 700 million investment

Intuitive Fosun's Medical Robot Manufacturing and R&D Center started construction in Shanghai

The proportion of direct sales revenue on the medical beauty platform increased to 66%

Strengthened its global operational capabilities and added direct sales team in the U.K. and Dubai

Ranked 1st among China's non-public hospitals in terms of competitiveness for 5 consecutive years

Foshan Fosun Chancheng Hospital passed the Joint Commission International (JCI) accreditation with high score

12 major specialty alliances

Emphasizes the construction of disciplines with the establishment of specialty alliances including obstetrics and gynecology, cardiology, orthopedics. The team of leading experts in various specialties including urology, orthopedics, nephrology, and rehabilitation have made significant progress

RMB 5.89 billion

Fosun Pharma's R&D investment in 2022

249

Patents applied in the pharmaceuticals segment

China's first approved CAR-T cell therapy

Yi Kai Da 奕凯达® (ejilunsai injection)
As of the end of January 2023, it had benefited more than 300 patients with relapsed or refractory large B-cell lymphoma; the indication for second-line treatment was accepted in October 2022 and has been included in the list of priority review products

Azvudine tablets

Fully commercialized in China and included in the National Medical Insurance Drug Catalogue 2022; 6.74 million bottles delivered as of the end of 2022

More than 10 million

Surgeries operated by the da Vinci Surgical System

Launched 3 new products on the medical beauty platform

1) Alma Ted™, an Ultrasound-based treatment for hair loss
2) Professional Injectable Fillers Skincare Solution™
3) LMNT one™, a home-use beauty device

10 Internet hospital licenses

Has been integrating offline medical institutions and Internet medical platforms, and establishing online medical and healthcare services since 2021

6,333 beds[1]

In member hospitals
1 It refers to the number of beds in member hospitals as of the end of 2022

HAPPINESS

Develop contents, models and products for families to link online platforms and offline scenarios

YUYUAN

As one of the flagship platforms of Fosun's Happiness segment, Yuyuan takes oriental lifestyle aesthetics as the key strategy to promote Chinese culture to the world, creating happier lives for families worldwide

Jewelry and Fashion

老庙 | 亞一 让爱相随 | DJULA PARIS | LUSANT

Food and Beauty

绿波廊 | 南翔馒头店 | 上海老饭店 | 杏花楼 | 松鹤楼 Song helou | 松鹤楼 苏式汤面 SUZHOU NOODLES

Chinese Watches

SEA-GULL 海鸥 | 上海 SHANGHAI since 1955

Liquor

复豫酒业 FUYU GROUP | 舍得酒业 SHEDE SPIRITS | 夜郎古酒

Beauty & Health

同涵春堂 TONG HAN 1783 CHUN TANG | AHAVA | WEI

FOSUN TOURISM GROUP

As a flagship platform of the Happiness segment, Fosun Tourism Group (FTG) is the world's largest leisure tourism resorts group, and is striving to create a new concept of "Better Holiday, Better Life", infusing evolving concepts of tourism and leisure into everyday living

Club Med 地中海俱乐部 | ATLANTIS SANYA 三亚·亚特兰蒂斯 | 复游会 Foryou Club

LANVIN GROUP

A grand transformation. Lanvin Group has entered the new phase of global development

LANVIN PARIS | sergio rossi | Wolford | ST. JOHN | CARUSO

MORE HAPPINESS

Focusing on sports, e-sports, film and television, games and other content to create a diversified entertainment experience of Fosun

Wolverhampton Wanderers FC | Lovelink

4,592

Points of sale

YUYUAN GARDEN LANTERN FESTIVAL

Inspired by Shanhaijing, also known as "the Classic of Mountains and Seas", the lantern festival attracted more than 4 million visitors; recommended by national media platforms and agencies stationed abroad

Time-honored brands with heritage; Bring brands to the global stage to reshape their future

Tong Han Chun Tang and AHAVA brands have developed rapidly

Operating nearly 70 resorts on six continents around the world

Plan to open 17 new resorts from 2023 to 2025; in 2022, Club Med recorded a business volume of RMB12.011 billion, an increase of 108% compared to 2021

Lanvin Group Gone Public

On 15 December 2022, Lanvin Group was listed on the New York Stock Exchange (NYSE) under the ticker symbol "LANV", becoming China's first global luxury goods group listed on the NYSE

Approx. 1,200

Lanvin Group's brands points of sale

8 championships and 3 runners-up

E-sports teams under Fosun Sports have accumulatively won 8 championships and 3 runners-up in various competitions, setting a record high

167 shops

Songhelou Suzhou-style noodle shop has 167 shops in 16 cities across the country

Two Chinese watchmakers

One Chinese chip

The High Quality Track of the Liquor Industry

Shede Spirits adheres to the "aged spirits strategy", the "multi-brand matrix strategy", the "brand rejuvenation strategy" and the "internationalization strategy" ; exported to 25 countries and regions

Sanya's Tourism 3.0 Benchmark

In the first two months of 2023, Atlantis Sanya's business volume fully recovered and exceeded pre-pandemic levels, with an average room occupancy rate of 96%

80+

Lanvin Group's brands covering more than 80 countries and regions

Approx. 300

Lanvin Group's brands self-operated retail stores

One of the founding members of the English Football League

Fosun's Sports' Wolverhampton Wanderers F.C. in the Premier League has won 11 league titles, 4 FA Cups and 2 League Cups

WEALTH

Fosun actively expands into household finance, corporate finance, investment businesses and hive city globally and accelerates the development of innovative finance driven by technology. Fosun continuously strengthens the seamless docking capability of "Industry + Finance", capturing opportunities of global industrial integration

INSURANCE

Establish a global presence and adhere to innovative development and insurance ecosystem development

FIDELIDADE SEGUROS DESDE 1808 · PeakRe · La Positiva Seguros · 复星保德信 Pramerica FOSUN · FOSUN HEALTH 复星联合健康保险

RMB 60.3 billion

Premium

RMB 160.7 billion

Investable assets

29.6%

Fosun Insurance Portugal's market share in Portugal in 2022

1 million+

Number of registered users of My Fidelidade APP

INVESTMENT MANAGEMENT

Industrial investment + financial investment as twin-driver to empower Health, Happiness, Wealth, and Intelligent Manufacturing in every stage of life

HAUCK AUFHAUSER LAMPE · Millennium bcp · FOSUN CAPITAL 复星创富 · 复星锐正 FOSUN RZ CAPITAL · NAGA · Guide. · FOSUN WEALTH 复星财富 · RIOBRAVO

EUR 257 billion

Assets under HAL's service and management

+12%

Growth in assets under HAL's service and management

EUR 1.86 billion

BCP's consolidated core net income

+44.4%

BCP's YOY consolidated core net income growth

China's Top 6 Most Recognized Private Equity Firms by LPs in 2022
China's Top 11 Private Equity Firms in 2022

Fosun Capital

China's Top 100 Venture Capital Firms in 2022

Fosun RZ Capital

HIVE

Introduce industries to cities to facilitate urban development, creating a global urban hive benchmark

FOSUN HIVE 复星蜂巢 · FORTE 复地 · 复星国际中心 FOSUN INTERNATIONAL CENTER · BFC THE BUND FINANCE CENTER 外滩金融中心 · IDÉRA CAPITAL MANAGEMENT · PAREF · RESOLUTION PROPERTY · 28 LIBERTY

40+

Global Fosun Hive Cities

130+


Global Fosun Hive Projects

THE GRAND YUYUAN

A global fashion cultural zone showcasing the charm of oriental lifestyle aesthetics

INTELLIGENT MANUFACTURING

Develop digital intelligence globally to empower industrial manufacturing
Fully implement the C2M model and leverage big data, artificial intelligence, IoT, and other emerging technologies to promote intelligent manufacturing



70.667 billion

Nanjing Iron & Steel's revenue in 2022

4.83 billion

Hainan Mining's revenue in 2022, +17.26% YOY

20,000 tons

The battery-grade lithium hydroxide project invested by Hainan Mining has begun construction

3.56 billion

Wansheng's revenue in 2022

More than 80%

YOY growth of FFT (Shanghai)'s newly signed orders during the reporting period

FOSUN'S STRATEGY

FOCUSED STRATEGY TO EMPOWER THE SUSTAINABLE GROWTH : FOUR CORE COMPETENCIES TO DRIVE CORPORATE GROWTH

PROFOUND GLOBAL OPERATIONS

Combining global resources with global growth momentum
Driven by China and the World
Global organization + local operations

INNOVATION-DRIVEN

Driven by product innovation
Driven by digital intelligence innovation
Driven by management innovation


FC2M[1] ECOSYSTEM

Improve C2M capabilities and create species
Link species, form ecosystem, and achieve multiplier growth
Enhance industrial capabilities through comprehensive digital intelligence to connect all ecosystems

1 FC2M: "F" represents Fosun and family, C2M represents Client to Maker

FES SYSTEM

Fosun Entrepreneurship / Ecosystem System
Provide systematic methodology, tools and processes to realize Fosun's globalization, innovation and ecosystem operation
Improve operational capabilities to create a sustainable operation system



PROFOUND GLOBAL OPERATIONS

GLOBAL FOOTPRINTS

Established profound industry operations in nearly 35 countries and regions across five continents in the world

GLOBAL BUSINESSES

More than 40% of the revenue comes from countries/regions outside China

GLOBAL INNOVATION

Focus on the Americas, Africa, India and Europe, build differentiated regional and global capabilities

GLOBAL TALENTS

More than 20 overseas partners among over 150 global partners

2010-Beginning : Globalization 1.0

Combining China's growth momentum with global resources

2017-Deepening : Globalization 2.0

Mutual empowerment between China and the world

2022-Evolution : Globalization 3.0

Global organization + local operations

44%	35+	40+	20+	45,000+
Sales revenue from overseas countries and regions	Countries and regions with revenue exceeding 100 million	Overseas brand enterprises	Overseas global partners	Overseas employees
Cross-cultural and cross-organizational capability	Digital intelligence capability	FES global management and operation system	Global innovation capability	Global investment capability



INNOVATION-DRIVEN

R&D investment in 2022

10.4 billion[1]

Strengthen technology innovation capability

(RMB)

1,771

Patents for inventions

10+

Global technology innovation centers

LEADING
CORE TECHNOLOGIES IN VARIOUS FIELDS

Innovative drug: focus on core therapeutic areas such as oncology, immunology, central nervous system, and chronic disease, and mainly strengthen core technology platforms such as small molecule, antibody/ADC, cell therapy, and RNA

Vaccine: platforms of bacterial vaccine + viral vaccine

Device: three major platforms of medical cosmetology + respiratory health + professional medical care

Research and application of **oriental lifestyle aesthetics**

Construction of the 4D technology innovation system: five senses of consumers + technology innovation R&D + creative design + technology innovation digitalization

Insurance: digital platform optimizes customer experience throughout the life cycle

Intelligent travel: full-stack self-developed L2+ intelligent driving software and hardware solutions

Industrial automation: leveraging digital twin, machine vision and other technologies accumulated for many years in the industry, AIGC large models are introduced to promote the industry's fully intelligence and automation

New energy: from traditional energy to the upstream extension of new energy and new materials

INNOVATIVE
TECHNOLOGY INNOVATION CENTERS IN VARIOUS FIELDS

Fosun Pharma Global R&D Center (national level)

JEVE Technology Center (national level)

Wanbang Biopharma Quality Department QC Lab[2] (CNAS certified)

Fosun Jinmei Global Technology Innovation Center[2]

Fosun Pharma North America R&D Headquarters

Shanghai Key Laboratory of Stem Cell Therapy

Sichuan Engineering Technology Center for Intelligent Brewing of Baiju

Lanvin Group Design Center (Milan,Italy and the U.K.)

Yuyuan Jewelry Creative House

Yuyuan Food & Culture Group Innovation Center Base

Academician Enterprise Research Institute

...

Han Si Zhuang 汉斯状®

Henlius

The world's first anti-PD-1 monoclonal antibody for first-line treatment of small cell lung cancer

Three indications have been approved in China (excluding Hong Kong SAR, Macau SAR and Taiwan region)

Vi Kai Da 奕凯达®

FOSUNKite 复星凯特生物

The first CAR-T cell therapy approved for launch in Chinese mainland

The indication for second-line treatment of adult large B-cell lymphoma was accepted in China (excluding Hong Kong SAR, Macau SAR and Taiwan region) and has been included in the list of priority review products

13-valent pneumococcal conjugate vaccine

FOSUN PHARMA 复星医药

Phase III clinical trial commenced in China (excluding Hong Kong SAR, Macau SAR and Taiwan region)

YOGAN

豫园股份 YUYUAN Inc.

The first self-developed skin care brand for sensitive skin, YOGAN was launched

Shede Spirits

舍得酒业 SHEDE SPIRITS

Tackling the technical solution of "upgrading and processing base spirit with special new materials that maintain the characteristics of the aged base spirit"

Fidelidade

FIDELIDADE SEGUROS DESDE 1808

The number of registered users of My Fidelidade APP exceeded 1 million, the proportion of medical reimbursement on the APP accounted for > 46%, and the proportion of digital auto insurance claims > 48%

Fusionride Technology

复睿智行 FUSIONRIDE

Launched a fusion sensing solution centered on high-performance 4D millimeter-wave radar

Easun Technology

翌耀科技 EASUN TECHNOLOGY

The self-developed new energy system was delivered to major overseas customers for the first time

Hainan Mining

海南矿业 HAINAN MINING

The 20,000-ton lithium hydroxide project (Phase I) invested by Hainan Mining has begun construction.

Hainan Mining is actively promoting the merger and acquisition and development of the Bougouni lithium mine in Mali, Africa

1 It includes scientific research investment (expensed and capitalized), but excludes digitalization expenses

2 Application of CNAS (China National Accreditation Service for Conformity Assessment) certified laboratory is in progress

FC2M ECOSYSTEM

Overview of Fosun's ecosystem: intelligent connection, open coopetition, global empowerment, multiplier development
Strategy of Fosun's ecosystem: make a concerted effort to strive for a common goal and share rewards to realize multiplier effect within the ecosystem

复星星选 FOSUN ALLIANCE

Membership Platform of Fosun's Ecosystem

FOSUN HEALTH 复星健康

Medical-grade, all-scenario, one-stop health ecosystem

SCENARIOS

INDUSTRIES

PLATFORMS

464 million
Cumulative number of operational members[1], an increase of 50.80 million members compared to 2021

6.9 billion (RMB)
Total value created by the Group's ecosystem[2]

133
Products with sales exceeding RMB100 million


22.58 million
Cumulative number of registered members of Fosun Health with 9.24 million new registered users in 2022

6.40 million
Cumulative number of registered members of Fosun Alliance, and the transaction conversion rate[3] under accurate recommendation increased by 26%



F C 2 M

FOSUN/FAMILY CLIENT LINK PRODUCTS AND SERVICES



1 Operational members: customers who have agreed to the official membership terms of the brand and granted privacy in any channel, and actively retained personal information including mobile phone numbers, to meet the needs of identifiable, reachable and traceable consumers are defined as registered members (i.e. operational members). From 2022 onwards, this statistic includes consumers in the Fosun Health ecosystem
2 It refers to the revenue contribution (before intercompany eliminations) directly or indirectly created by companies within the Fosun ecosystem for other companies within the ecosystem, including but not limited to cross-selling, product co-creation, membership contribution, membership sales transformation, and sales collaboration within the ecosystem, joint industrial investment, financing cooperation empowerment, industrial resource coordination, etc.
3 It refers to order conversion rate, facilitating order placement by sending marketing materials to users, as calculated by "number of users placing orders/number of users reached"

Notes:
1. The companies are listed according to the consolidated financial statement of Fosun International
2. The companies are some of the strategic suppliers of Fosun
3. The companies are some of the strategic partners of Fosun

FES SYSTEM

FES

(Fosun Entrepreneurship / Ecosystem System)

The FES system is a continuously evolving management system that helps Fosun build core competitiveness of a longstanding enterprise and nurture talents with Fosun's entrepreneurship

The system provides Fosun with systematic methodology, tools, and processes to realize Fosun's global operations capabilities, globalization, technology innovation and smooth operation of Fosun's ecosystem

With the joint effort of all employees, a corporate culture of continuous improvement and continuous growth will be established, promoting the contribution of the "Power of Fosun" to the development of the whole society






Profound Industry Operations + Industrial Investment

Accumulation

Practice



100+
Professional tools

700+
Expert certifications annually

40+
Improvement activities annually

100+
FES best practice cases

FOCUS ON KEY TALENTS TO BUILD A TEAM WITH ENTREPRENEURIAL SPIRITS

Talents, the most valuable asset of Fosun
A robust team of talents determines the scalability of the company's future development





ELITE MANAGEMENT TEAM

150+ global partners
280+ industry partners,
400+ functional line partners
70+ innovation partners,
with regular rotation to deeply involve
in each project, sector, and region

GLOCAL

20+ overseas
global partners
coming from countries
including Portugal, France,
Germany, the U.K., Japan,
India, and the U.S.

FOSUN'S TALENT DEVELOPMENT STRATEGY

Attract talents with
development, appraise talents
based on performance,
train talents through work,
and unite talents
with career opportunities

Build a multi-level and multi-dimensional partner system,
incentivize partners, and adhere to a market-based, benefit-sharing entrepreneurial mechanism

FOSUN GLOBAL PARTNERS

300 +
Future Fosun global partners

MID-LEVEL ENTREPRENEURS

3,000 +
Future entrepreneur backups

FUTURE ENTREPRENEURS

30%
High-potential talents

TECHNOLOGY INNOVATION TALENTS

100 +
Top scientists of Fosun ecosystem

Future Fosun Global Partners Backups

Build a 'pyramid-shaped' partner backup array,
forming a competitive dynamic partnership management mechanism that allows talent appraisals at different levels according to their performance



OUR PURSUIT

REMARKABLE ESG ACHIEVEMENTS FOR A BRIGHTER LIFE

MSCI ESG RATINGS AA
CCC B BB BBB A AA AAA
LAST UPDATE: December 27, 2021

The only conglomerate in Greater China with a MSCI ESG rating of AA

Hang Seng Corporate Sustainability Index Series A


S&P Global

S&P CSA ESG score outperformed 91% of global peers and was significantly above the industry average score

FTSE Russell

Selected as one of the constituents of FTSE4Good Index Series for the first time in 2022

ESG RATINGS CONTINUED TO IMPROVE IN 2022



E

CARBON NEUTRALITY STRATEGY

- Achieve carbon neutrality goal by 2050
- EHS management framework
- Climate risk response

S

FOSUN FOR GOOD

- Rural Doctors Program
- Assist the World Health Organization (WHO) in building a malaria-free world
- Deploy anti-epidemic materials globally, "Drug + Vaccine" to build a health protection barrier

G

CORPORATE GOVERNANCE

- Continue to optimize and evolve corporate risk management
- Improve ESG governance structure with the new establishment of an ESG Executive Committee and an ESG Management Committee
- Actively communicate with external investors and rating agencies on ESG issues

FOSUN FOR GOOD



The Fosun Foundation was established in November 2012 as the main humanitarian arm of the Fosun Group and is a "5A Social Organization". Adhering to Fosun 's philosophy of "Self-improvement, Teamwork, Performance and Contribution to Society", Fosun Foundation insists on serving the society, the people and the nation. The coverage of the foundation includes disaster relief, healthcare, poverty alleviation, rural revitalization, education, community building, youth entrepreneurship and culture, art, etc., serving many countries and regions around the world

FOSUN FOUNDATION (SHANGHAI)

Fosun Foundation (Shanghai) is a non-profit organization launched and supported by the Fosun Group and Fosun Foundation. Its programs are characterized by contemporary, international, and highly interactive artworks. It has held a total of 26 art exhibitions and has attracted more than 1.62 million visitors since 2016

ASSIST AFRICA IN FIGHTING AGAINST MALARIA

Fosun Pharma supplied over 280 million artesunate injections to the international market, benefited over 56 million patients with severe malaria. Fosun Pharma has 30 anti-malarial drugs were prequalified by the World Health Organization (WHO Prequalified Lists)

RURAL DOCTORS POVERTY ALLEVIATION PROGRAM

Up to now, the program has covered 73 counties in 16 provinces, municipalities, and autonomous regions
Sent a total of 226 staff to assist the counties
Served approx. 24,000 rural doctors
Benefited 3 million grassroots families

PROTECHTING GLOBAL YOUTH START-UP ACCELERATION PROGRAM

Received 896 applications from 40+ countries and regions since 2016
Won 3 international awards in recognition of its corporate social responsibility
33 closely cooperated start-up projects
5 companies signed commercial contracts

TAI CHI ANTI-PARKINSON'S DISEASE, TAI CHI FOR DELAYING ALZHEIMER'S DISEASE

The scientific research findings of Tai Chi as an adjuvant therapy for chronic diseases were published in international authoritative journals
Organized 3,144 hours of Tai Chi charitable courses for 445 patients with Parkinson's disease since 2015
Organized 945.5 hours of online Tai Chi charitable courses, benefited 23,491 people since 2020

FOSUN FOUNDATION (SHANGHAI)

Fosun Foundation (Shanghai) aims to promote contemporary art and is committed to binding Chinese and international art and culture, and promote public awareness, understanding and engagement in global contemporary art. Fosun Foundation (Shanghai) continues to support local Chinese artists, providing a broad display platform for outstanding Chinese contemporary art works. Fosun Foundation (Shanghai) is located in the Bund Finance Center. Fosun Foundation (Chengdu) was opened in June 2022. Fosun Foundation (Shanghai) participates in, witnesses and leads the development of contemporary art and culture. As an art consultant, Fosun Foundation (Shanghai) has long showcased its collection of Chinese art works in global landmark buildings such as Liberty 28 in New York to promote global cultural and artistic exchanges

26 art exhibitions

1.62 million + visits

Committed to presenting international and Chinese contemporary art exhibitions and special exhibitions with rich content, including “Tadao Ando: Endeavors”, “Yayoi Kusama: All About Love Speaks Forever”, etc.

500 public education campaigns

39,120+ people participated in public education campaigns

Insist on organizing high-quality public education campaigns to help the public understand art and promote active participation in art-related events

370+ Fosun Foundation (Shanghai) Night and Aesthetic Journey

Organize diversified and comprehensive cross-brand activities to promote public awareness and public engagement in the latest contemporary art trends


The first 3A social organization among Shanghai contemporary art institutions

The first governing unit of Shanghai Art Museum Association

Shanghai Municipal Administration of Culture and Tourism's "Civilization and Integrity, Art Appreciation" co-construction unit, Shanghai Public Welfare Base, Donghua University Aesthetic Education Practice Base











RURAL DOCTORS PROGRAM

Delivering hope to impoverished people in rural areas

The Rural Doctors Program is one of the key initiatives to realize the goal of common prosperity. In late 2017, under the guidance of the National Health Commission Poverty Relief Office, Fosun Foundation, together with China Population Welfare Foundation, etc., initiated the Rural Doctors Poverty Alleviation Program (“Rural Doctors Program”) to empower millions of rural doctors who are working in the frontlines, thereby accelerating the realization of Healthy China

6 years, 315

On-site workers

16

Provinces, cities, autonomous regions covered across the country

73

Key national poverty-stricken counties

(including 13 counties in Three Regions and Three Prefectures in extreme poverty, which have all lifted out of poverty)

12,545

Administrative village clinics assisted

23,956

Rural doctors served

3 million

Grass-root families benefited

The Rural Doctors Program was awarded the "China Charity Award" in September 2021 and the “Shanghai Charity Award” in December 2022







FIGHT AGAINST MALARIA IN AFRICA

Assisting in building a “malaria-free world”

280 million +

The number of vials of artesunate for injection (60mg) that Fosun Pharma supplied to the global market since 2005, according to incomplete statistics

56 million +

The number of patients with severe malaria that Artesun® (artesunate for injection) has saved

175 million

The number of children in high malaria transmission African countries benefited from SPAQ-CO ®Disp, a malaria prevention drug for children which was prequalified by the World Health Organization

“We will join forces and work with anti-malaria experts as well as other parties to continue to carry out malaria education projects for the public and raise the public awareness of malaria prevention. We will also actively participate in public health improvement and make steady efforts to build a malaria-free world.”

——Guo Guangchang





TAI CHI ANTI-PARKINSON'S DISEASE, TAI CHI FOR DELAYING ALZHEIMER'S DISEASE

Slow therapy for chronic disease to hold on to the good memories

Fosun Foundation cooperated with the Neurology Department of Ruijin Hospital to jointly launch "Tai Chi Anti-Parkinson's Disease" and "Tai Chi for Delaying Alzheimer's Disease"


TAI CHI ANTI-PARKINSON'S DISEASE

520
Patients with Parkinson's disease served since 2015

3,144 hours
Offline course

945.5 hours
Online course

23,491
Participants online


Cell Death & Disease

Explore content · About the journal · Publish with us

nature › cell death & disease › articles › article

Article | Open Access | Published: 03 October 2018

Reduction of HIP2 expression causes motor function impairment and increased vulnerability to dopaminergic degeneration in Parkinson's disease models

Jinlin Su, Pei-Huang, Meiling Qin, Qingqing Lu, Xiao Sang, Yiyun Cai, Ying Wang, Fubing Liu, Rong Wu, Xiaoqing Wang, Xiaoxing Jiang, Jian Wang, Qiang Sun, Shengdi Chen & Jin Xu

Cell Death & Disease 9, Article number: 1020 (2018) | Cite this article

1989 Accesses | 13 Citations | 4 Altmetric | Metrics

In 2018, the research article titled "Reduction of HIP2 expression causes motor function impairment and increased vulnerability to dopaminergic degeneration in Parkinson's disease models" was published in Cell Death & Disease

TAI CHI FOR DELAYING ALZHEIMER'S DISEASE

53
Patients with Alzheimer's disease served

167.5 hours
Tai Chi charitable course organized (offline)

COMMUNITY TAI CHI VOLUNTEER INSTRUCTOR TRAINING

5
Community served

147
Elders served

1,764
Elders benefited in the community

88
Tai chi volunteers trained


BMC Part of Springer Nature

Translational Neurodegeneration

Home About Articles Submission Guidelines Submit manuscript

Research | Open Access | Published: 07 February 2022

Mechanisms of motor symptom improvement by long-term Tai Chi training in Parkinson's disease patients

Gen Li, Pei Huang, Shi-Shuang Cui, Yu-Yan Tan, Ya-Chao He, Xin Shen, Qin-Ying Jiang, Ping Huang, Gui-Ying He, Bin-Yin Li, Yu-Xin Li, Jin Xu, Zheng Wang & Shang-Di Chen

Translational Neurodegeneration 11, Article number: 6 (2022) | Cite this article

5719 Accesses | 10 Citations | 3 Altmetric | Metrics

In February 2022, the research article titled "Mechanisms of motor symptom improvement by long-term Tai Chi training in Parkinson's disease patients" was published in Translational Neurodegeneration

ALZHEIMER'S ASSOCIATION · Howard Hughes Med Inst MIT · Search

JOURNALS

Alzheimer's & Dementia®

THE JOURNAL OF THE ALZHEIMER'S ASSOCIATION

FEATURED ARTICLE


Tai Chi enhances cognitive training effects on delaying cognitive decline in mild cognitive impairment

Binyin Li, Huidong Tang, Guiying He, Zhijia Jin, Yixi He, Fei Huang, Naying He, Shengdi Chen

First published: 15 March 2022 | https://doi.org/10.1002/alz.12658 | Citations: 3

Binyin Li, Huidong Tang, Guiying He, and Zhijia Jin contributed equally to this work.

In March 2022, the research article titled "Tai Chi enhances cognitive training effects on delaying cognitive decline in mild cognitive impairment" was published in Alzheimer's & Dementia



FIGHT AGAINST COVID-19: STAY TRUE TO OUR ORIGINAL ASPIRATION AND CONTRIBUTE TO SOCIETY

ASSIST THE GLOBAL FIGHT AGAINST COVID-19

(From 24 January 2020 to 3 April 2023)



SUPPORT CHINA'S FIGHT AGAINST COVID-19

Deployed nearly 3 million pieces of materials globally

These strategic materials provide strong support for China's fight against COVID-19

When the COVID-19 pandemic broke out in early 2020 and China was in the most difficult time, Fosun leveraged its strong global resources deployment capability to source medical supplies from 23 countries

On 28 January 2020, the first batch of materials deployed by Fosun, 50,000 pieces of protective suits deployed from Germany, was delivered from Frankfurt to front-line medical staff in Wuhan and other front-line medical staff in just 5 days

Provided a total of more than 6.245 million pieces of materials in Shanghai's battle against COVID-19

As of 9 June 2022, anti-epidemic materials donated by Fosun Foundation and its partners to support the three projects, "Community Support", "Care for Elderly" and "Care for Children" in Shanghai's battle against COVID-19

Over the past three years in the fight against the pandemic, Fosun has continued to assist Wuhan, Sanya, Nanjing, Beijing, Xi'an, Zhengzhou, Shanghai, Hong Kong, Shenzhen, etc.

CONTRIBUTION TO SOCIETY

147 million pieces
Medical supplies deployed; such as COVID-19 nucleic acid testing kits, ventilators, face masks, protective suits, and gloves, for humanitarian relief support against COVID-19

Assisted 30+ countries
Fosun's self-developed COVID-19 nucleic acid detection kit has been certified by the China NMPA and the U.S. Food and Drug Administration (FDA), and obtained the European Union CE marking

18,000+
Ventilators put into use in the global flight against COVID-19

20,000+
Oxygen concentrators provided to support India's fight against COVID-19

100,000
Pieces of KN95 face masks

"DRUG + VACCINE" TO ASSIST THE GLOBAL FIGHT AGAINST COVID-19

31 million doses of Comirnaty

Had been administered in Hong Kong, Macau and Taiwan regions as of the end of February 2023

Following the rollout of the self-paid vaccination service of Comirnaty BNT162b2 original vaccine in Macau in 2022, the self-paid vaccination service for Comirnaty Bivalent Vaccine has been rolled out in Hong Kong and Macau in the first quarter of 2023, providing more vaccine options for people in need and helping to build a health protection barrier

Donated Azvudine tablets to 250 counties and cities across the country

In 2022, Azvudine tablets, China's first small molecule oral medication for COVID-19 jointly developed by Fosun Pharma and Henan Genuine Biotech, was included in the national Diagnosis and Treatment Protocol for COVID-19 and was covered by the national medical insurance scheme. At the beginning of 2023, the Fosun Foundation, together with Fosun Pharma and Genuine Biotech, launched the campaign "A Healthy Winter Action" to donate Azvudine tablets to 250 counties and cities across the country, helping the grassroots weather the epidemic during the New Year